Merck Receives FDA Fast Track Designation for Evofosfamide
Advanced pancreatic cancer is second indication to receive FDA fast track designation for evofosfamide
18-May-2015 -
Merck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally ...
cancer
evofosfamide
Fast Track status
+2